Article

jdsupra.com on 2021-01-13 20:45

FDA Defers Decision on Bevacizumab Biosimilar

The FDA has deferred its decision on the biologics license application for MYL-1402O, Mylan and Biocon’s biosimilar to Avastin® (bevacizumab). In a ...

Related news

Celltrion’s Bevacizumab Biosimilar Approved by FDA jdsupra.com
Japan , United States
FDA Accepts Samsung Bioepis’s Bevacizumab Biosimilar (SB8)jdsupra.com
California , United States , Switzerland
FDA Advisory Committee to Hold Public Meetings on Amgen’s Proposed Bevacizumab Biosimilar and Mylan’s Proposed Trastuzumab Biosimilar jdsupra.com
Maryland , Silver Springs , Manage
FDA Issues CRL for Biocon/Viatris Bevacizumab Biosimilar jdsupra.com
FDA Issues Draft Guidance on Biosimilar Interchangeability jdsupra.com
Genentech Sues Centus Over Proposed Bevacizumab Biosimilar jdsupra.com
Texas , Jilin , Kyowa-cho , Sues
FDA Announces Advisory Committee Meeting on Sandoz’s Etanercept Biosimilar jdsupra.com
FDA Updates Select Q&As on Biosimilar Regulation jdsupra.com
Reg
FDA Issues Revised Guidance on Biosimilar Development and BPCIA jdsupra.com
FDA Approves 25th Biosimilar jdsupra.com
California , United States , Switzerland
FDA to Hold Public Meeting on Biosimilar User Fees jdsupra.com
Maryland , Silver Spring , White Oak
FDA Issues Final Guidance on “Labeling for Biosimilar Products”jdsupra.com
California , United States , Switzerland
FDA Issues Draft Guidance on Demonstrating Biosimilar Interchangeability jdsupra.com
FDA seeks industry input on biosimilar guidance development jdsupra.com
FDA Seeks Input on Biosimilar Product Development Guidance jdsupra.com
FDA Approves Amneal’s ALYMSYS (bevacizumab-maly)jdsupra.com
FDA Issues Draft Guidance on Labeling For Biosimilar Products jdsupra.com
FDA Revises Guidance on Switching Studies for Biosimilar Interchangeability jdsupra.com
Amneal Launches Bevacizumab Biosimilar in the United States jdsupra.com
United States